https://www.theedgemarkets.com/article/top-gloves-fair-value-could-surpass-rm110-affin-hwang-says

If topglov...@50.00...then comfort will be...@8.00... if...@100.00...then how...comfort...16.00...???

tamp0i Wow HLG TP 0.48? Will we really see this price kah? Exciting leh
21/07/2020 8:02 PM

I Q so long at...@0.48...when can match...???

Top Glove accorded ‘A’ rating in recent social audit by Amfori | https://www.klsescreener.com/v2/news/view/705299

Big Bros n leader of gloves industry good news n upswing...all smaller gloves counters also upswing together tomorrow...those he didn't take advantage during minor corrections, need to wait another chance.

Top Glove breaches SOP under RMCO | https://www.klsescreener.com/v2/news/view/705277

Lot of sour grapes when gloves counters all shooting straight up like rockets...Especially against Topglov...n now this issue...Anyway I bought it when it was below @5.00...sold by @10.00, then bought Comfort n then Ruberex...nobody knew it keeps on shooting up...even smaller n not well established counters, like Careplus n Adventa, plus other related counters. But only gloves counters n occasionally tech counters have more liquidity flowing in n out, for quite a long run. Probably due to suspension of shortselling until year end, gloves n others profit growth counters will outperform until January 2021.

Predict_Future @geary, above 4.5 maybe ? HAHAHA end of this week 5.0 above !
21/07/2020 5:46 PM

My target was...@4.80...stsrt from 4th week of June...within 50 days...see how overall markets sentiments...◉‿◉

Predict_Future thanks team, completed my mission today, those panic sell, i love you so much !!!!!
21/07/2020 4:56 PM

Tomorrow Upswinging...!!!

tuapuikia compulsory on a face mask at public should be good news for ocncash.

Singapore is compulsory...caught without mask on... $300 fine...Japanese n Taiwanese they wear mask because of social responsibility if they got flu...But those Angmoh thought they are superheroes...protests...so let them spread covid 19 with their human right unreasonable attitudes...because they like to kiss n have closed contacts hands n faces...they call these love...That's ignorance or stupidity caused human beings to suffer this fate...!!!

Added...@3.54...!!!

Ha...Gloves counters...all Rest today...tired of running up the stairs for too long...Must take some oxygen mah...will start to run up 2morrow...!!!

dalpinia Switched all to Pharm & Dpharma!!! Bye bye glove!!!
21/07/2020 3:19 PM

Whatever pharma selling vaccine n other drugs that's...don't command higher profits margins than gloves...so the PE multiply won't be so high as gloves counters...n thier earnings growth much lower gloves products...with higher demand at present periods...｡◕‿◕｡

foongkitmun Drop more!!!!!
21/07/2020 3:12 PM

Q at...@3.80...◉‿◉

One day show maybe...Sell take Profit...◉‿◉

MingGoon Comfort...
Very soon KYY said so cheap Comfort
and Comfort another new high soon
21/07/2020 2:37 PM

Uncle KYY become swing or day trader lah...◉‿◉

opportunity sold all comfort and park all here ady
21/07/2020 11:17 AM

｡◕‿◕｡

China nuclear option...if unleash will be bearish for markets...!!!
https://www.scmp.com/economy/china-economy/article/3094014/china-bought-more-us-debt-may-despite-talk-financial-war-amid

Hwai Hooi turn to comfort liao
20/07/2020 7:36 PM

Psychological advantage or disadvantage...let see the market tomorrow...ʘ‿ʘ

Uncle KYY article,

In view of all these complications, the price charts can help investors to make good investment decision. The 3 charts below show the price movement of Comfort, Top Glove and Supermax in the last 6 months.

Comfort shot up from 90 sen to close at Rm 4.11, an increase of 457%.

Top Glove shot up from Rm 6.50 to close at Rm 24.80, an increase of 382%

Supermax shot up from Rm 2.00 to close at Rm 18.40, an increase of 920%.

Based of the above comparison, investors should sell Supermax to buy Top glove and Comfort. I prefer to buy Top Glove because it is more than double the size of Supermax in terms of manufacturing capacity and a world leader in this glove business.

Ha...Wake up already Uncle...look closely n become chartist...◉‿◉

Bursa hits fresh record volume of nearly 12.5b shares | https://www.klsescreener.com/v2/news/view/704641

Liquidity power...!!!

Trading Bought...@3.56...◉‿◉

papparich Wow...kick out all the small fries first
20/07/2020 4:44 PM

Traders paradise...but not for the faint hearted...◉‿◉

Lelouch Eddie Liang geary , dato will dispose high and buy low
recently dato buy alot LHI at 0.60 sen
20/07/2020 3:07 PM

They are professional traders...margin account or pledged security...they don't wait for margin call...buy high sell higher...high Risk management...!!!

Max2838 Dato Lau last sale transaction in June about RM 3.00
Dato Lau latest buy transaction in July about RM 3.67
Why does Dato know that we don't?
Covid, more glove demand, higher ASPs ? Everybody knows that.
You can guess as much as you can about the ASPs, but only Directors know the exact ASP for every month from July to December.....
20/07/2020 12:29 PM

Insider buying is a positive sentiment...probably more to come like bonus issue...◉‿◉

Geopolitical tension...!!!

https://www.scmp.com/news/china/diplomacy/article/3093762/us-has-lost-its-mind-morals-and-credibility-chinas-foreign

secretinvestor8888 rubbish.... throw this... buy KOSSAN, SUPERMAX, SUPERMAX WARRANTS
19/07/2020 4:41 PM

Supermax...already a ten baggers...for those bought 3th week of March...@1.50...those who didn't...Sell or don't know when to sell...n still using margin...are looking for trouble later on...U didnt Sell means U didn't Win...!!!

Commentary: As world waits for coronavirus vaccine, antibodies treatment a needed plan B
Funding organisations must invest more resources to overcome hurdles in developing antibody treatments for the coronavirus, say observers.

Needed plan B at present momentum...so demand for gloves, masks, n ppe still exceed supply...Hold...!!!

chesslim Ocncash now betul betul game over lah.....bye bye all investor who buy at 0.825 above.
17/07/2020 5:15 PM

Around present price...@0.625...U must execute...ha...@0.825...almost zero margin of safety...!!!

110 containers with toxic waste from Romania abandoned at PTP | https://www.klsescreener.com/v2/news/view/704241

Migrant workers Human right lah...palm oil deforestation lah...biased ideology...why dumped all the toxic rubbish in Asia...???

Airasia Group BHD
KLSE: AIRASIA

0.74 MYR 0.00 (0.00%)
17 Jul, 5:00 pm MYT ·
Disclaimer
0.52 MYR ‎Thu, 19 Mar 2020.

Mar 19, '20...@0.52...That’s below floor value...at the time...how many bought...chance only one time...if right issue probably...@0.80-@1.00...!!!...PS or PP...indicative price was...@1.00...!!!

nicky Dato Lau starts to acquire....
19/07/2020 3:10 PM

Critical thinking...calculated risks...he needs to execute at the right time...!!!

KUALA LUMPUR (July 19): When COVID-19 first started to send cataclysmic waves through the global equity market, glove maker counters were among those that had bucked the trend and skyrocketed due to a sudden surge in demand for disposable rubber gloves from both the medical and non-medical sectors.

Shares of homegrown rubber glove manufacturer, Top Glove Corporation Bhd had spiked more than 400 per cent year-to-date, creating more job opportunities during the pandemic.

However, on Thursday, the United States Customs and Border Protection (US CBP) imposed a detention order on imports from two of its subsidiaries, Top Glove Sdn Bhd and TG Medical Sdn Bhd, placing the companies on its Withhold Release Order (WRO) list.

The move saw Top Glove’s share price plummeting by 10 per cent to RM19.70, although trading was later halted by Bursa Malaysia due to technical issues.

Top Glove stocks were not the only casualties on Thursday’s trading, as its main competitors, Hartalega Holdings Bhd, Supermax Corporation Bhd and Kossan Rubber Industries Bhd also took a hit, which resulted in a total of RM10 billion worth of market capitalisation wiped out from the local bourse in a single day.

Top Glove said the WRO may be related to foreign labour issues which is expected to be resolved within the next two weeks or a month.

This was not the first time the glove maker had been put in a tough position by the US CBP.

In December 2018, the company faced the same predicament after a British daily, The Guardian, reported that its migrant workers were allegedly subjected to forced labour, forced overtime and debt bondage, and had their wages withheld and passports confiscated.

Top Glove, however, denied the allegations, and exports had resumed as usual.

Migrant Worker’s Issue: A Global Concern

When COVID-19 started to spread across the globe, the US Embassy in Kuala Lumpur tweeted that 65 per cent of medical gloves used by US frontliners had been made in Malaysia.

“Through the production of medical gloves and other medical products, the world relies on Malaysia in the fight against COVID-19,” it said.

However, in June, Britain’s Channel 4 reported that migrant workers were only paid £1.08 an hour (RM5.77) and were forced to work overtime to meet the demand for gloves during the COVID-19 pandemic.

Putting things in the Malaysian context, a wage of RM5.77 per hour is considered as standard payment, even for Malaysians who work as part-timers in the food and beverages industry.

Meanwhile, in the United Kingdom (UK), public service union assistant general secretary Christina McAnea said the UK government had treated its migrant workers in a “shameful way.”

“Migrant workers are in the frontline of the fight against COVID-19 in care homes, propping up a neglected system that would collapse without them.

“Hundreds of thousands of care jobs are unfilled, yet the government is intent on cutting off a source of skilled workers just when the UK needs them the most,” reports quoted her as saying.

In the US, media reports said that migrant workers were either turned away or barred from receiving treatment for COVID-19.

On the contrary, migrant workers in Malaysia -- both legal and illegal -- had received adequate treatment and care.

It is important to understand that Malaysia is not the only country to deal with issues posed by migrant workers.

It is a universal issue which requires global attention. Cherry picking on the matter would not help solve it.

US Detention Order - A temporary dent

An equity analyst said that the WRO would only have a temporary impact on Top Glove’s stocks as well as those of other glove makers.

“The foreign investors’ interest in Top Glove’s shares remain sturdy as it holds a huge market share in badly affected nations, especially the US,” she said.

According to Top Glove’s annual report for financial year 2019 (FY2019), the North America region -- comprising the US and Canada -- accounted for 27 per cent of its sales volume.

It noted that the sales volume to the region leapt by 20.3 per cent in FY2019 compared with FY2018.

As the world’s largest rubber glove manufacturer, Top Glove commands a 26 per cent share of the global market, with a production capacity of 80.2 billion pieces per annum.

As of July 17, the company’s market capitalisation stood at RM62 billion.

Besides rubber gloves, the company had also ventured into manufacturing other essential healthcare products such as the three-ply mask to address the shortage due to the pandemic, condoms, as well as dental care products.

At Friday’s close, the company’s shares on Bursa Malaysia rose 16.65 per cent to close at RM22.98, with a total of 56.56 million shares traded, erasing its losses from the previous day.

On the Singapore Exchange, its shares rebounded 15.87 per cent to settle at S$7.52.

According to research notes, Top Glove is expected to continue its bullish momentum and the uptrend is not expected to end anytime soon.

Comfort market cap Rm 2.262 billion divided by 5.9 billion gloves = 38 sen per glove.

Supermax market cap Rm 24.07 billion divided by 25.7 billion gloves = 94 sen per glove.

Based on my above calculation, Comfort is so much under-priced. That is why RHB OSK has Rm 4.80 target price for Comfort Glove.


Total for the year profit Rm 275.3 million

Total issued shares 580 million

EPS 47 sen

Based on P/E 20 target price Rm 9.40

Based on P/E 15 target price Rm 7.05

Based on P/E 10 target price Rm 4.70

Ya...These are FA...there are TA to consider...plus intrinsic value of management team...macro n economic...geopolitical factors...interest rates...supply n demand for its outstanding share...n present sentiments of its products.

Belinda I missed the boat.
18/07/2020 10:00 PM

Probably it's half way...so u need a helicopter to jump inside...so your price will be higher...sell before the clock strike midnight...◉‿◉

Good123 How billionaires become millionaires: investing in airlines

After 2 years from now...millionaires become billionaires again...hehehe...!!!

skyhin Sure boh, can justify cal ?
18/07/2020 6:52 PM

Of course there are various variables...like vaccine...macroeconomics n geopolitical to consider...if using only TA n FA...Probably within 1 year around...@8.80...!!!

xuxu @geary you are here, comfort is the MUST buy stock now.
14/07/2020 2:46 PM

Already bought last 4th week of June...

By 2021 January...TP...@6.80...!!!

Uncle KYY today.

Common sense will tell you that the Covid 19 pandemic will not be under control for at least another 6 months and the demand for gloves will continue to exceed supply.

You can avoid stress and worry if you just buy and hold for a few months. You don’t need a crystal ball or consult a fortune teller to tell you that the price for Supermax and other glove stocks will continue to go up higher and higher until the pandemic is under control.

President Trump banned 5G technology - Koon Yew Yin - Koon Yew Yin's Blog | I3investor

President Trump banned 5G technology - Koon Yew Yin
Author: Koon Yew Yin Publish date: Fri, 17 Jul 2020, 7:06 PM

US banned Huawei 5G technology. Huawei is the world's No. 1 telecom supplier and No. 2 phone manufacturer, but it's a pariah in countries like the US. Unfortunately, UK Prime Minister Boris Johnson, like an obedient dog wants to follow Trump to ban Huawei 5G networking equipment despite Huawei phone’s massive presence around the world. The US continues to pressure allies to block Huawei from their next-generation 5G wireless networks. In July, the UK opted to ban Huawei from its 5G infrastructure. The company's gear must be removed by 2027.

Donald Trump and Boris Johnson are so ignorant as they did not realise how much this new technology can help the people and the nations improve economically. Trump does not care as long as he can bash China to win more votes for his re-election in November. Unfortunately, most Americans also like to degrade China. All Americans and British people should open their eyes to read the following to know more about 5G technology.

What is 5G technology?

The new, faster standard will make possible what is frequently called the Internet of Things—the wireless connection of everyday items to allow data on them to be collected, analysed, and manipulated. These items could be anything, including mundane household appliances, farm equipment, watches and clocks, water mains, various robots, hospital devices, and even the computers and machines used by businesses and emergency services—all could be networked together, accessed, and monitored online. 5G will enable self-driving cars to communicate with each other and with traffic monitoring systems—potentially preventing accidents by reacting up to 200 times faster than human drivers. There is a world of possibilities and potential just waiting for the mind of man to explore it.

The big focus of 5G enthusiasm is about the vast increase in computing capabilities that will result from massive improvements in communication and extraordinary amounts of data transfer. Experts believe these developments may have the potential to generate a new Industrial Revolution, producing jobs and boosting national economies. Estimates suggest that in the next few years we could see literally millions of 5G base stations on Earth and 20,000 new 5G satellites in low Earth orbit, connected to 200 billion transmitting objects.

Wider rollout of 5G, however, is going to take significant investment and time before it reaches our neighbourhoods. Compared to 4G signals, which blanket the airwaves in all directions, 5G, at frequencies of 10 to 300GHz (gigahertz) and a one-millimetre wavelength, is unable to pass through buildings or trees and can even be disrupted by rainfall. To overcome these difficulties, 5G phased-array base antennas, transmitting multiple narrow, steerable, high-power signals, need to be positioned just 200 metres apart in a grid. The same antennas in all 5G devices, either stationary or moving, will seek to establish a continuous connection with the base antennas. Existing legislation will permit these signals to be at least ten times more powerful (up to 20 watts) than current 4G signals.

Ha...KYY can understand better than those pariah n lapdogs...!!!

NEW YORK CITY: The US is pinning its hopes on a COVID-19 coronavirus vaccine, but will a vaccine alone be enough to stop the pandemic and allow life to return to normal?

The answer depends on a how “good” the vaccine ends up being.

In a study published on Jul 15 in the American Journal of Preventive Medicine, my colleagues and I used a computer simulation of every person in the country to show how effective a vaccine would have to be and how many people would have to get vaccinated to end the pandemic.

We found that a coronavirus vaccine’s effectiveness may have to be higher than 70 per cent or even 80 per cent before Americans can safely stop relying on social distancing.

By comparison, the measles vaccine has an efficacy of 95 per cent to 98 per cent, and the flu vaccine is 20 per cent to 60 per cent.

IMPORTANCE OF AN EFFECTIVE VACCINE

Some political leaders have suggested that society will return to normal soon, especially if a vaccine becomes available by the end of the year or early in 2021. Some vaccines are currently in early-stage trials, but that timeline would still be very optimistic.

However, it is important to remember that a vaccine is like many other products: What matters is not just that the product is available but also how effective it is.

FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe
Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration taken taken on Apr 10, 2020. (Photo: REUTERS/Dado Ruvic)
Different vaccines may offer different levels of protection. Scientists talk about this as the vaccine’s efficacy or effectiveness.

If 100 people who haven’t been exposed to the virus are given a vaccine that has an efficacy of 80 per cent, that means that on average 80 of them would not get infected.

The difference between efficacy and effectiveness is that the former applies when vaccination is given under controlled circumstances, like a clinical trial, and the latter is under “real-world” conditions. Typically, a vaccine’s effectiveness tends to be lower than its efficacy.

Since COVID-19 coronavirus vaccines are still under development, now is the time to set vaccine efficacy levels to aim for, as well as to manage expectations. Running computer simulations is really the only way to ethically do this.

Typically, in an epidemic or pandemic, as more people are exposed to the virus, the number of new infections per day steadily increases until it reaches a peak and begins to drop. Of course, how long this takes depends upon how the virus and the response to it may evolve over time.

To stop the pandemic, the number of new infections per day needs to drop to zero, or at least to a very low number, as quickly as possible.

If the COVID-19 pandemic were just beginning and the population infected was close to 0 per cent, the simulations show that vaccine efficacy would have to be at least 60 per cent to stop the coronavirus if the entire population was vaccinated.

Given the number of susceptible people who couldn’t be vaccinated because of age or health problems and the number who would refuse to be vaccinated, that’s probably impossible.

Trading of glove stocks is not for the uninitiated and faint-hearted

BURSA Malaysia is not a market for retailers. Some 30% of the index weighting is on glove stocks – namely Top Glove Corp Bhdand Hartalega Holdings Bhd.

On a single day, the price of the four glove stocks can gyrate anywhere between 20% and 30% and it is accompanied by huge volumes, which suggests that it is a playing ground for the funds as well as punters.

In a single day last week, Supermax Corp Bhd, which is among the top four glove companies, gyrated as much as RM5.30. It went as high as RM17.80 and as low as RM12.50, before closing the day at RM15.90.

A normal investor would probably have had a heart seizure. Anybody who had bought the stock at the peak with the view of selling on the same day would have lost his or her pants.

The story is the same for all the other glove stocks. The price gyration is scary, to say the least. The stocks are up in the morning before coming down late afternoon and picking up strongly by the end of the trading day.

Clearly, it is not the kind of market for retailers. It’s only for those who are really experienced in trading and understand the dynamics of jumping in and out without getting hurt.

Some research houses have tagged unprecedented valuations on glove stocks. It’s surprising that even the foreign houses have raised the price of the top-notch glove companies such as Top Glove and Hartalega to more than RM30. Credit Suisse’s target for Top Glove is RM37.

Glove stocks are trading at historical price earnings (PE) multiple of between 75 time and 170 times at current prices. Among the four glove manufacturers, the stock with the highest PE multiple is Supermax while Kossan Rubber Industries Bhdis at the lowest end at 75 times PE.

If the stocks hit the price targets as set out by the research houses, we are looking at Supermax possibly trading at almost 200 times PE and Top Glove at more than 120 times PE. The mind-boggling valuations are jaw-dropping but analysts seem to suggest that the stocks have the earnings potential.

Are analyst reports reliable?

The upgrade in price targets by research houses suggests that there is an impending earnings explosion of the companies in the second quarter. But what the research houses fail to stress is the sustainability of the earnings.

To the pessimist on glove stocks, they would say that analyst reports certainly are not a yardstick as they are just forecast numbers and not any indication to buy or sell the stock.

However, to be fair, some research houses had predicted Top Glove to be RM25 a month ago when it was barely touching RM15. Then, many had dismissed the price target as nonsensical. Now, RM25 seems to be a reasonable price for Top Glove for some.

Amidst the optimism surrounding glove stocks, it’s interesting to note that the major shareholders of Kossan have disposed of a little of their holdings in the market. The family of Tan Sri Lim Kuang Sia, who control Kossan and are known for not selling their shares even when prices were high, sold a few million shares in recent weeks.

The family still retains a substantial 47% in Kossan. Their move to take some money off the table is something that should not be dismissed. It’s a clear signal that glove stocks are looking over-valued.

The interest on glove stocks is so huge that it is said to be responsible for the crash of Bursa Malaysia’s trading system on Thursday. The crash came as there was heavy selling on glove stocks following news that the US authorities have stopped some shipments of Top Glove’s exports to that country.

The US market accounts for 25% of Top Glove’s exports and gives the highest average selling prices for the gloves. Hence, the impact is significant on Top Glove.

The announcement was out during the lunch break although news of the consignment being stopped seeped into the market in the morning. Top Glove resumed trading at 3.30pm. Shortly later, the system crashed.

Brokers feel that the crash came about because of the heavy sell order for glove stocks, which is not surprising considering the volume these stocks garner.

The run on the glove stocks is a reminder of the dotcom run in 1999 when semiconductor producers namely Malaysian Pacific IndustriesBhd and Unisem Bhd were the darlings of the stock market.

The stocks were on an uptrend for almost a year before the dotcom crash in 2000. The two stocks hit ballistic valuations that not many fund managers had envisaged. Until today, the two stocks are still considered the bell-weather for the tech sector.

But now there are many more players in the tech sector. They are diversified into several segments within the sector and Technology is an index within Bursa itself.

Similarly, the play on glove companies is now focused on the top four stocks. The others are enjoying the run on the sector. If demand for gloves continues, the sector will likely see more new names emerging on the stock market.

KUALA LUMPUR (July 18): Malaysia needs to have the capability to produce critical products, said Prime Minister Tan Sri Muhyiddin Yassin.

He said this covered the food and beverage sector, medical devices, medicines, petrochemicals, and personal protective equipment like gloves and face masks.

"When the country has this capability, we can reduce the outflow of the Malaysian currency and increase the export of local products,” he said when launching the national-level Mega Sales Programme and Buy Malaysian Products Campaign at Suria KLCC here today.

Therefore, the government is studying and review the existing policies to reduce dependence on imported products and give priority to building the capacity of local industries to produce made in Malaysia products, he added.

Covid19 Pandemic.

The first case was reported in China in early January and it took three months to reach 1 million cases. It has taken just four days to climb to 14 million cases from 13 million recorded on July 13.

Global coronavirus infections passed 14 million on Friday, according to a Reuterstally, marking the first time there has been a surge of 1 million cases in under 100 hours.

The first case was reported in China in early January and it took three months to reach 1 million cases. It has taken just four days to climb to 14 million cases from 13 million recorded on July 13.

The United States, with more than 3.6 million confirmed cases, is still seeing huge daily jumps in its first wave of COVID-19 infections. The United States reported a daily global record of more than 77,000 new infections on Thursday, while Sweden has reported 77,281 total cases since the pandemic began.

Despite the surging cases, a cultural divide is growing in the country over wearing masks to slow the spread of the virus, a precaution routinely taken in many other nations.

U.S. President Donald Trump and his followers have resisted a full-throated endorsement of masks and have been calling for a return to normal economic activity and reopening schools despite the surging cases.

Other hard-hit countries have “flattened the curve” and are easing lockdowns put in place to slow the spread of the novel virus while others, such as the cities of Barcelona and Melbourne, are implementing a second round of local shutdowns.

The number of cases globally is around triple that of severe influenza illnesses recorded annually, according to the World Health Organization.

The pandemic has now killed more than 590,000 people in almost seven months, edging towards the upper range of yearly influenza deaths reported worldwide. The first death was reported on Jan. 10 in Wuhan, China before infections and fatalities then surged in Europe and later in the United States.

The Reuters tally, which is based on government reports, shows the disease is accelerating the fastest in the Americas, which account for more than half the world’s infections and half its deaths.

In Brazil, more than 2 million people have tested positive including President Jair Bolsonaro, and more than 76,000 people have died.

India, the only other country with more than 1 million cases, has been grappling with an average of almost 30,000 new infections each day for the last week.

Those countries were the main drivers behind the World Health Organization on Friday reporting a record one-day increase in global coronavirus cases of 237,743.

In countries with limited testing capacity, case numbers reflect only a proportion of total infections. Experts say official data likely under-represents both infections and deaths. - Reuters

Flights increase gradually by August...!!!
https://www.businesstraveller.com/business-travel/2020/07/17/singapore-airlines-to-increase-flights-in-august/

Covid19 Vaccine in September.

British pharma giant AstraZeneca is "on track" to begin rolling out up to two billion doses of a coronavirus vaccine in September if ongoing trials prove successful, its chief executive said on Friday.

The company is partnering with Oxford University, which has pioneered the vaccine, and is already manufacturing doses before seeking final regulatory approval once testing concludes in the coming months.

"So far we're still on track... we are starting to manufacture this vaccine right now, and we have to have it ready to be used by the time we have the results," AstraZeneca chief executive Pascal Soriot told BBC radio.

"Our present assumption is that we will have the data by the end of the summer, by August, so in September we should know whether we have an effective vaccine or not."

The firm announced this week it had struck agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India to double production capacity of the COVID-19 vaccine to two billion doses.

The partnership with the Indian institute—one of the world's largest vaccine manufacturers—will help supply it to a large number of low- and middle-income countries.

AstraZeneca has established separate supply chains for the vaccine in Europe, the United States, India and is also looking at setting up production in China, Soriot said.

He added AstraZeneca, which is undertaking the work on a non-profit basis, could lose money if trials prove disappointing.

But he said the company was sharing the financial risk with organisations such as CEPI.

"We're manufacturing indeed at risk—and that's the only way to have the vaccine ready to go if it works," he added.

Oxford University began initial trials of its COVID-19 vaccine with hundreds of volunteers in April, and is now expanding them to 10,000 participants.

It said last month they were "progressing very well".

Researchers announced this week they will also start tests in mid-June in Brazil, the first country outside Britain to take part in the study, as the South American country's virus infection rate spirals while the UK's falls.

Chinese vaccine candidate effective against all known coronavirus strains: Sinopharm
By Fan Wei Source: Global Times Published: 2020/7/16 16:20:26
15
We are racing with the virus, not the US: Sinopharm president

A Chinese-developed inactivated COVID-19 vaccine candidate is effective against all detected strains of the virus so far, with lower chance and degree of adverse reactions than same-typed vaccine candidates under research, the head of the vaccine candidate's producer told the Global Times in an exclusive interview on Monday.

"The inactivated vaccine we developed can cover all strains of the coronavirus that have been detected so far, including the virus strains tracked in the Xinfadi market in Beijing," Yang Xiaoming, president of China National Pharmaceutical Group (Sinopharm), noted in response to public concerns that the vaccine under the R&D process would be ineffective as the virus mutates.

The research team has carried out cross-protection experiments to test if the anti-serum obtained by immunizing animals can produce an immune response to different genotypes of strains of coronavirus, Yang said.

Sinopharm, whose COVID-19 inactivated vaccine candidates have been delivered into phase three clinical trials, have stored more than 4 million doses of the vaccines, the Global Times learned from the group.

Yang said that the group is currently storing more COVID-19 vaccines. Once a candidate is approved for the market, the company will soon be able to provide as many doses of vaccines as the country needs.

Yang estimated that an inactivated COVID-19 vaccine will be available on the market at the end of this year or early 2021. Two inactivated COVID-19 vaccine candidates separately developed by Sinopharm institutes in Beijing and Wuhan entered clinical trials in April.

The results of phase one and two clinical trials of the two candidates were revealed in June, showing that all receptors have created high-titer antibodies.

Skepticism and pessimism of Chinese-developed COVID-19 vaccines have been raised in some Western media, which have exaggerated the side effect ratio reported in early-stage clinical trials of another vaccine candidate, the Ad5-nCoV recombinant novel coronavirus vaccine.

Vaccine experts advised the public not to panic over the side effects revealed in the preliminary results of the Chinese-developed coronavirus vaccine, as the adverse reactions exposed are tolerable and the vaccine is under constant optimization.

Yang also reveals that more than 1,000 Sinopharm group employees have been receiving injections on a voluntary basis, and the results show a promising trend that the vaccine is safe and effective, with low incidence and degree of adverse reactions.

At the end of May, 180 volunteers from Sinopharm received inactivated COVID-19 vaccinations, and their antibodies have reached levels resistant to the coronavirus with a 100 percent protective rate.

On June 23, Sinopharm signed agreements with the United Arab Emirates (UAE) government to conduct COVID-19 vaccine candidate phase three clinical trials in the country, the world's first COVID-19 vaccine candidate phase three clinical trials to have been launched.

China's National Medical Products Administration on Thursday stressed the need to promote the development and marketing of COVID-19 vaccines, and take the initiative to help pharmaceutical companies resume work and production.

As China and the US have been given great hopes on providing panacea for the coronavirus, their respective vaccine R&D pace has drawn much media attention. Some have called the vaccine development "a race between two countries currently caught in strained ties."

Leading US medical expert Anthony Fauci expressed his confidence in prospects for the US vaccine on Wednesday, and said he does not expect China to win the vaccine race, Reuters reported.

"The COVID war between the US and China is looking like a race to the moon. Being first to develop COVID treatments and vaccines has become a point of national pride," Lawrence Gostin, the director of Georgetown University's O'Neill Institute for National and Global Health Law, was quoted as saying in the report of Business Insider. "A 'my country first' attitude is highly counterproductive. We need to work cooperatively as a global and scientific community."

"We are racing with the coronavirus but not with the US [to be the first with successful vaccine]", Yang argued, claiming that all their efforts are part of China's commitment to make the vaccine available to the international community.

Yang said he hopes to see Chinese-developed vaccines against coronavirus accessible and affordable for developing countries when they turn out. He expects further global cooperation in COVID-19 vaccine trials to help stop the pandemic that has infected millions.

Chinese vaccine candidate effective against all known coronavirus strains: Sinopharm
By Fan Wei Source: Global Times Published: 2020/7/16 16:20:26
15
We are racing with the virus, not the US: Sinopharm president

A Chinese-developed inactivated COVID-19 vaccine candidate is effective against all detected strains of the virus so far, with lower chance and degree of adverse reactions than same-typed vaccine candidates under research, the head of the vaccine candidate's producer told the Global Times in an exclusive interview on Monday.

"The inactivated vaccine we developed can cover all strains of the coronavirus that have been detected so far, including the virus strains tracked in the Xinfadi market in Beijing," Yang Xiaoming, president of China National Pharmaceutical Group (Sinopharm), noted in response to public concerns that the vaccine under the R&D process would be ineffective as the virus mutates.

The research team has carried out cross-protection experiments to test if the anti-serum obtained by immunizing animals can produce an immune response to different genotypes of strains of coronavirus, Yang said.

Sinopharm, whose COVID-19 inactivated vaccine candidates have been delivered into phase three clinical trials, have stored more than 4 million doses of the vaccines, the Global Times learned from the group.

Yang said that the group is currently storing more COVID-19 vaccines. Once a candidate is approved for the market, the company will soon be able to provide as many doses of vaccines as the country needs.

Yang estimated that an inactivated COVID-19 vaccine will be available on the market at the end of this year or early 2021. Two inactivated COVID-19 vaccine candidates separately developed by Sinopharm institutes in Beijing and Wuhan entered clinical trials in April.

The results of phase one and two clinical trials of the two candidates were revealed in June, showing that all receptors have created high-titer antibodies.

Skepticism and pessimism of Chinese-developed COVID-19 vaccines have been raised in some Western media, which have exaggerated the side effect ratio reported in early-stage clinical trials of another vaccine candidate, the Ad5-nCoV recombinant novel coronavirus vaccine.

Vaccine experts advised the public not to panic over the side effects revealed in the preliminary results of the Chinese-developed coronavirus vaccine, as the adverse reactions exposed are tolerable and the vaccine is under constant optimization.

Yang also reveals that more than 1,000 Sinopharm group employees have been receiving injections on a voluntary basis, and the results show a promising trend that the vaccine is safe and effective, with low incidence and degree of adverse reactions.

At the end of May, 180 volunteers from Sinopharm received inactivated COVID-19 vaccinations, and their antibodies have reached levels resistant to the coronavirus with a 100 percent protective rate.

On June 23, Sinopharm signed agreements with the United Arab Emirates (UAE) government to conduct COVID-19 vaccine candidate phase three clinical trials in the country, the world's first COVID-19 vaccine candidate phase three clinical trials to have been launched.

China's National Medical Products Administration on Thursday stressed the need to promote the development and marketing of COVID-19 vaccines, and take the initiative to help pharmaceutical companies resume work and production.

As China and the US have been given great hopes on providing panacea for the coronavirus, their respective vaccine R&D pace has drawn much media attention. Some have called the vaccine development "a race between two countries currently caught in strained ties."

Leading US medical expert Anthony Fauci expressed his confidence in prospects for the US vaccine on Wednesday, and said he does not expect China to win the vaccine race, Reuters reported.

"The COVID war between the US and China is looking like a race to the moon. Being first to develop COVID treatments and vaccines has become a point of national pride," Lawrence Gostin, the director of Georgetown University's O'Neill Institute for National and Global Health Law, was quoted as saying in the report of Business Insider. "A 'my country first' attitude is highly counterproductive. We need to work cooperatively as a global and scientific community."

"We are racing with the coronavirus but not with the US [to be the first with successful vaccine]", Yang argued, claiming that all their efforts are part of China's commitment to make the vaccine available to the international community.

Yang said he hopes to see Chinese-developed vaccines against coronavirus accessible and affordable for developing countries when they turn out. He expects further global cooperation in COVID-19 vaccine trials to help stop the pandemic that has infected millions.

wehcant geary, friends think I was crazy to bet on Comfort early this year. I remember that time, most people were talking about where to buy face masks in bulk and resell for a premium. A friend even went to India to source for face masks.
17/07/2020 5:00 PM

Foresight...Caculated Risks...Patience...Boring Time...Success...◉‿◉

wehcant Who said you can't make your first million in stocks trading?
17/07/2020 4:49 PM

Power...◉‿◉

Mabel I'm still waiting for my 60 sen

Meow..
17/07/2020 3:56 PM

Me too...◉‿◉

xuxu geary next week will stand above 4.0 hehe
17/07/2020 4:50 PM

Yup...(◔‿◔)

@3.90...(◠‿◕)

xuxu yesterday added now good profit already hehe.